Derm EXTRA Flashcards

1
Q

Risk factors for SCC

A
  • Excess sun/psoralen UVA
  • Actinic keratoses + Bowen’s disease
  • Immunosuppression
  • Smoking
  • Chronic leg ulcer
  • Xeroderma pigmentosum, oculocutaneous albinism
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Seborrhoeic dermatitis - associated underlying conditions

A

HIV

Parkinsons

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Seborrhoiec dermatitis - management of scalp disease - 1st line

A

OTC preparations containing zinc pyrithione or tar

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Seborrhoiec dermatitis - management of scalp disease - 2nd line

A

Ketoconazole

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Seborrhoiec dermatitis - face + body management

A

Topical antifungals: ketoconazole

Topical steroids for short periods

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Erythematous facial rash sparing the nasolabial folds

A

Acne rosacea

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Erythematous facial rash involving the nasolabial folds

A

Seborrhoeic dermatitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Antibodies present in bullous pemphigoid

A

Anti-hemidesmosomes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Skin biopsy immunofluorescence - shows IgG and C3 at dermoepidermal junction

A

Bullous pemphigoid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Features of BCC (“rodent ulcer”)

A

Initially - Pearly, flesh-coloured papule, telangiectasia

Later - ulceration + central crater

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Features of Bowen’s disease

A

Red, scaly patches
Slow-growing
Sun-exposed areas

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Features of pyogenic granuloma (“eruptive haemangioma”)

A

RAPID growth
from small red/brown SPOT,
to raised red/brown spherical lesion
within days/weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Diagnostic test for pemphigus vulgaris

A

Direct immunofluorescence of skin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Features of granuloma annulare

A

Smooth annular flesh-coloured lesion.
No scale

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Tinea corporis (ringworm): features

A

Annular erythematous plaque
Scale
Well defined, raised edges
May have pustules/papules

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Management of granuloma annulare

A

Await resolution
Topical steroids if itch/cosmetic concern

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Fungal body skin infection/Ringworm/Tinea corporis
- Candida possible

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Fungal body skin infection/Ringworm/Tinea corporis
- 1st line for Adult

A

Topical Terbinafine 1% Once/Twice daily for 1 week (NWL)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Management of vitiligo

A

Oral steroids and azathioprine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Vitiligo vs pityriasis versicolor

A

Vitiligo likely to be associated with other auto-immune diseases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Features of dermatofibroma (histiocytoma)

A

Benign fibrous skin lesion
Pinch test > forms a dimple

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Features of BCC

A

Sun-exposed - head & neck
Pearly papule
Prominent telangiectasia
Later ulcerates > crater

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

BCC - commonest treatment

A

Surgery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Features of keratoacanthoma

A

Dome shaped
Symmetrical
Keratotic/necrotic core
Rapid growth (months)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Treatment of keratoacanthoma

A

Urgent excision to exclude SCC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Features of SCC

A

Initially scaly erythematous patch

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Treatment of SCC

A

Surgical excision

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Treatment of metastatic melanoma

A

Pembrolizumab (PD-1 receptor blocker)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Features of actinic keratoses

A

Erythematous plaques
Sun-exposed area

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Treatment of actinic keratoses

A

Topical 5-FU/diclofenac/salicyclic acid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Risk factors for SCC

A
  • Excess sun/psoralen UVA
  • Actinic keratoses + Bowen’s disease
  • Immunosuppression
  • Smoking
  • Chronic leg ulcer
  • Xeroderma pigmentosum, oculocutaneous albinism
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Seborrhoeic dermatitis - associated underlying conditions

A

HIV

Parkinsons

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Seborrhoiec dermatitis - management of scalp disease - 1st line

A

OTC preparations containing zinc pyrithione or tar

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Seborrhoiec dermatitis - management of scalp disease - 2nd line

A

Ketoconazole

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Seborrhoiec dermatitis - face + body management

A

Topical antifungals: ketoconazole

Topical steroids for short periods

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Erythematous facial rash sparing the nasolabial folds

A

Acne rosacea

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

Erythematous facial rash involving the nasolabial folds

A

Seborrhoeic dermatitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

Antibodies present in bullous pemphigoid

A

Anti-hemidesmosomes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Skin biopsy immunofluorescence - shows IgG and C3 at dermoepidermal junction

A

Bullous pemphigoid

40
Q

Features of BCC (“rodent ulcer”)

A

Initially - Pearly, flesh-coloured papule, telangiectasia

Later - ulceration + central crater

41
Q

Features of Bowen’s disease

A

Red, scaly patches
Slow-growing
Sun-exposed areas

42
Q

Features of pyogenic granuloma (“eruptive haemangioma”)

A

RAPID growth
from small red/brown SPOT,
to raised red/brown spherical lesion
within days/weeks

43
Q

Diagnostic test for pemphigus vulgaris

A

Direct immunofluorescence of skin

44
Q

Features of granuloma annulare

A

Smooth annular flesh-coloured lesion.
No scale

45
Q

Features of tinea corporis

A

Annular erythematous plaque, with raised edge and scale

46
Q

Management of granuloma annulare

A

Await resolution
Topical steroids if itch/cosmetic concern

47
Q

Management of tinea corporis

A

Oral fluconazole

48
Q

Management of vitiligo

A

Oral steroids and azathioprine

49
Q

Vitiligo vs pityriasis versicolor

A

Vitiligo likely to be associated with other auto-immune diseases

50
Q

Features of dermatofibroma (histiocytoma)

A

Benign fibrous skin lesion
Pinch test > forms a dimple

51
Q

Features of BCC

A

Sun-exposed - head & neck
Pearly papule
Prominent telangiectasia
Later ulcerates > crater

52
Q

BCC - commonest treatment

A

Surgery

53
Q

Features of keratoacanthoma

A

Dome shaped
Symmetrical
Keratotic/necrotic core
Rapid growth (months)

54
Q

Treatment of keratoacanthoma

A

Urgent excision to exclude SCC

55
Q

Features of SCC

A

Initially scaly erythematous patch

56
Q

Treatment of SCC

A

Surgical excision

57
Q

Treatment of metastatic melanoma

A

Pembrolizumab (PD-1 receptor blocker)

58
Q

Features of actinic keratoses

A

Erythematous plaques
Sun-exposed area

59
Q

Treatment of actinic keratoses

A

Topical 5-FU/diclofenac/salicyclic acid

60
Q

Multiple scaly lesions, 2-4 weeks after sore throat

A

Guttate psoriasis

61
Q

1st line for mild impetigo

A

Topical hydrogen peroxide 1%

62
Q

2nd line for mild impetigo

A

Topical fusidic acid

63
Q

1st line for extensive impetigo

A

Oral flucloxacillin

64
Q

Treatment of extensive impetigo if pen-allergic

A

Oral erythromycin

65
Q

Drugs which induce TEN

A

Phenytoin
Carbemazepine
Allopurinol
Sulphonamides
Penicillins
NSAIDs

66
Q

1st line treatment of dermatophyte nail infection

A

Oral terbinafine

67
Q

1st line treatment of candidal nail infection

A

Topical amorolfine

68
Q

Dermovate (Clobetasol propionate 0.05%)

A

Very potent

69
Q

Cutivate (Fluticasone propionate 0.05%)

A

Potent

70
Q

Betnovate (Betamethasone valerate 0.1%)

A

Potent

71
Q

Betnovate RD (Betamethasone valerate 0.025%)

A

Moderate

72
Q

Eumovate (Clobetasone butyrate 0.05%)

A

Moderate

73
Q

Hydrocortisone 0.5-2.5%

A

Mild

74
Q

Management of periorifical dermatitis

A

Topical or oral antibiotics

75
Q

1st line for mild rosacea

A

Topical metronidazole

76
Q

1st line for scalp psoriasis

A

Topical potent corticosteroid (Betamethasone 0.1%)
Up to 4wks

77
Q

2nd line for scalp psoriasis
(after 4wks)

A

Different formulation of corticosteroid
+/-
Agent to remove scale

78
Q

3rd line for scalp psoriasis
(after 4 wks)

A

Calcipotriol-betamethasone
or
Vitamin D analogue (if mild-mod)

79
Q

Multiple scaly lesions, 2-4 weeks after sore throat

A

Guttate psoriasis

80
Q

1st line for mild impetigo

A

Topical hydrogen peroxide 1%

81
Q

2nd line for mild impetigo

A

Topical fusidic acid

82
Q

1st line for extensive impetigo

A

Oral flucloxacillin

83
Q

Treatment of extensive impetigo if pen-allergic

A

Oral erythromycin

84
Q

Drugs which induce TEN

A

Phenytoin
Carbemazepine
Allopurinol
Sulphonamides
Penicillins
NSAIDs

85
Q

1st line treatment of dermatophyte nail infection

A

Oral terbinafine

86
Q

1st line treatment of candidal nail infection

A

Topical amorolfine

87
Q

Dermovate (Clobetasol propionate 0.05%)

A

Very potent

88
Q

Cutivate (Fluticasone propionate 0.05%)

A

Potent

89
Q

Betnovate (Betamethasone valerate 0.1%)

A

Potent

90
Q

Betnovate RD (Betamethasone valerate 0.025%)

A

Moderate

91
Q

Eumovate (Clobetasone butyrate 0.05%)

A

Moderate

92
Q

Hydrocortisone 0.5-2.5%

A

Mild

93
Q

Management of periorifical dermatitis

A

Topical or oral antibiotics

94
Q

1st line for mild rosacea

A

Topical metronidazole

95
Q

1st line for scalp psoriasis

A

Topical potent corticosteroid (Betamethasone 0.1%)
Up to 4wks

96
Q

2nd line for scalp psoriasis
(after 4wks)

A

Different formulation of corticosteroid
+/-
Agent to remove scale

97
Q

3rd line for scalp psoriasis
(after 4 wks)

A

Calcipotriol-betamethasone
or
Vitamin D analogue (if mild-mod)